Whan In Pharm Co.,Ltd. (KRX:016580)
10,490
0.00 (0.00%)
At close: Sep 5, 2025
Whan In Pharm Revenue
Whan In Pharm had revenue of 64.14B KRW in the quarter ending June 30, 2025, with 0.81% growth. This brings the company's revenue in the last twelve months to 258.70B, up 6.70% year-over-year. In the year 2024, Whan In Pharm had annual revenue of 259.60B with 12.68% growth.
Revenue (ttm)
258.70B
Revenue Growth
+6.70%
P/S Ratio
0.62
Revenue / Employee
427.61M
Employees
605
Market Cap
160.15B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 259.60B | 29.20B | 12.68% |
Dec 31, 2023 | 230.39B | 31.46B | 15.81% |
Dec 31, 2022 | 198.93B | 21.16B | 11.90% |
Dec 31, 2021 | 177.78B | 6.07B | 3.54% |
Dec 31, 2020 | 171.71B | 12.53B | 7.87% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |